These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 21454037

  • 21. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK, Shelton CM, Sahni JK, Christensen ML.
    Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
    [Abstract] [Full Text] [Related]

  • 24. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M, Veyssier-Belot C, Alhenc-Gelas M, Chatellier G, Billaud-Mesguish E, Fiessinger JN, Aiach M.
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
    Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, Cayla G, Gallois V, Galier S, Costagliola D, Collet JP, Montalescot G.
    J Am Coll Cardiol; 2010 Feb 16; 55(7):617-25. PubMed ID: 20170785
    [Abstract] [Full Text] [Related]

  • 27. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial.
    Robinson S, Zincuk A, Larsen UL, Ekstrøm C, Nybo M, Rasmussen B, Toft P.
    Crit Care; 2013 Apr 19; 17(2):R75. PubMed ID: 23601744
    [Abstract] [Full Text] [Related]

  • 28. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
    Feng Y, Green B, Duffull SB, Kane-Gill SL, Bobek MB, Bies RR.
    Br J Clin Pharmacol; 2006 Aug 19; 62(2):165-76. PubMed ID: 16842391
    [Abstract] [Full Text] [Related]

  • 29. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S, Lemos PA, Esteves A, Ribeiro EE, Horta P, Nicolau JC, Ramires JA, Cohen M, Martinez EE.
    J Invasive Cardiol; 2006 Feb 19; 18(2):45-8. PubMed ID: 16446514
    [Abstract] [Full Text] [Related]

  • 30. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A, Held K, Oschman A.
    Pediatr Blood Cancer; 2014 Jun 19; 61(6):1063-7. PubMed ID: 24375987
    [Abstract] [Full Text] [Related]

  • 31. Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients.
    Helviz Y, Dzigivker I, Raveh-Brawer D, Hersch M, Zevin S, Einav S.
    Isr Med Assoc J; 2016 Feb 19; 18(2):108-13. PubMed ID: 26979004
    [Abstract] [Full Text] [Related]

  • 32. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS.
    Pharmacotherapy; 2007 Sep 19; 27(9):1263-71. PubMed ID: 17723080
    [Abstract] [Full Text] [Related]

  • 33. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A.
    Clin Pharmacol Ther; 2002 Sep 19; 72(3):308-18. PubMed ID: 12235452
    [Abstract] [Full Text] [Related]

  • 34. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG.
    Thromb Haemost; 2010 Dec 19; 104(6):1150-7. PubMed ID: 20886185
    [Abstract] [Full Text] [Related]

  • 35. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit.
    White H, Sosnowski K, Bird R, Jones M, Solano C.
    Blood Coagul Fibrinolysis; 2012 Jun 19; 23(4):304-10. PubMed ID: 22473047
    [Abstract] [Full Text] [Related]

  • 36. Experience with intravenous enoxaparin in critically ill infants and children.
    Crary SE, Van Orden H, Journeycake JM.
    Pediatr Crit Care Med; 2008 Nov 19; 9(6):647-9. PubMed ID: 18838932
    [Abstract] [Full Text] [Related]

  • 37. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sié P.
    Thromb Haemost; 1998 Feb 19; 79(2):338-41. PubMed ID: 9493587
    [Abstract] [Full Text] [Related]

  • 38. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J, Johnston N, Siegbahn A.
    Am Heart J; 2008 Mar 19; 155(3):493.e1-8. PubMed ID: 18294482
    [Abstract] [Full Text] [Related]

  • 39. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
    Kopelman TR, O'Neill PJ, Pieri PG, Salomone JP, Hall ST, Quan A, Wells JR, Pressman MS.
    Am J Surg; 2013 Dec 19; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
    [Abstract] [Full Text] [Related]

  • 40. Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients.
    Cronin BJ, Godat LN, Berndtson AE, Pham A, Kolan S, Box K, Lee JG, Costantini TW.
    Burns; 2019 Jun 19; 45(4):818-824. PubMed ID: 30827851
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.